Introduction
============

Organic anion transporter 2 (OAT2; SLC22A7) is a member of the SLC22A family, and is closely related to the multi-selective renal organic anion transporters, organic anion transporter 1 (OAT1; SLC22A6) and organic anion transporter 3 (OAT3; SLC22A8). OAT1 and OAT3 each share ∼37% amino acid identity with OAT2. In comparison, OAT1 and OAT3, which have distinct but also overlapping substrate selectivity, share ∼48% amino acid sequence identity to each other. Although OAT2 is present in the kidney, it is predominately expressed in the liver ([@B26]; [@B7]). The ligand selectivity and transport mechanism of OAT1 and OAT3 have been well characterized, and much attention has been placed on these transporters (among other select drug transporters) since they are known to influence the pharmacokinetics of numerous clinically relevant drugs, and because they represent potential sites of drug--drug interactions ([@B8]). In contrast, much less is known regarding the ligand selectivity and transport mechanism of OAT2, or its role in pharmacokinetics.

Several variants of the OAT2 peptide sequence have been reported in the literature. Transcript variant 1 (OAT2-tv1; GenBank accession number NP006663) and transcript variant 2 (OAT2-tv2; GenBank accession number NP696961) share 100% amino acid sequence identity, but OAT2-tv1 is two amino acids shorter ([@B5]) -- OAT2-tv1 and OAT2-tv2 contain 546 and 548 amino acids, respectively. [@B26] also identified two transcript variants, and named them hOAT2A and hOAT2B. hOAT2A and hOAT2B were reported to contain 546 and 538 amino acids, respectively, and it was suggested that they are likely alternatively spliced variants, which contain different C-terminal segments ([@B26]). However, the GenBank accession number AI016020 provided for hOAT2A and hOAT2B ([@B26]) is linked to a partial Expressed Sequence Tag sequence, and thus, the actual peptide sequences are unknown. [@B6] reported using an OAT2 construct that contains 539 amino acids. The peptide sequence for this variant is deposited in the National Center for Biotechnology Information (NCBI) database under GenBank accession\# AAG43523. For the purpose of this study, we have denoted this construct as OAT2-tv3. Compared to OAT2-tv1, OAT2-tv3 has a phenylalanine instead of leucine at amino acid position 302, and the C-terminal tail is truncated, with 10 out of its last eleven amino acids differing from the corresponding amino acids in OAT2-tv1 -- this may in fact be the hOAT2B sequence cloned by [@B26]. Supplemental Figure [S1](#SM1){ref-type="supplementary-material"} shows an amino acid alignment of the three OAT2 sequences identified to date.

Much of our knowledge of the ligand selectivity of OAT2 comes from studies using the cloned transporter expressed in heterologous expression systems. **Table [1](#T1){ref-type="table"}** provides a summary of studies that have examined the substrate selectivity of OAT2, showing the OAT2 construct and heterologous expression system used, along with the organic solutes that were identified as substrates. Importantly, many of the studies never cited the OAT2 sequence used, and the studies used several different heterologous expression systems, including S2 cells (immortalized S2 proximal tubule segment from mouse), human embryonic kidney (HEK) cells, Madin-Darby canine kidney (MDCK) cells and *Xenopus laevis* oocytes. More recent studies (2008 and after) examining the ligand selectivity of OAT2 have mostly used OAT2-tv1. These studies demonstrated that OAT2-tv1 is capable of transporting select guanine-containing antivirals ([@B4]), creatinine ([@B25]), orotic acid, and glutamate ([@B7]), select antineoplastic drugs ([@B20]) and select guanine nucleotides, including cGMP ([@B5]) (**Table [1](#T1){ref-type="table"}**).

###### 

Summary of studies that have examined the substrate selectivity of organic anion transporter 2 (OAT2).

  Study    Variant   Accession number   Expression system                     Substrates
  -------- --------- ------------------ ------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@B26]   ?         AI016020           HEK293                                *para*-aminohippurate, methotrexate, cAMP, α-ketoglutarate, fluorescein
  [@B3]    ?                            S2 cells                              Tetracycline, prostaglandin F2α
  [@B6]    tv3       AF210455           S2 cells                              Prostaglandin F~2~α
  [@B27]   ?                            S2 cells                              Prostaglandin F~2~α, zidovudine
  [@B14]   ?                            S2 cells                              Prostaglandin E~2~
  [@B12]   ?                            S2 cells                              Prostaglandin F~2~α, salicylate
  [@B11]   ?                            S2 cells                              Prostaglandin F~2~α
  [@B15]   tv2       AY050498           *Xenopus* oocytes                     Estrone-3-sulfate, bumetanide, glutarate, dehydroepiandrosterone sulfate, allopurinol, prostaglandin E~2~, 5-fluorouracil, paclitaxel, ascorbate, *para*-aminohippurate
  [@B16]   ?                            *Xenopus* oocytes                     Theophylline, erythromycin
  [@B5]    tv1       NM006672           HEK293                                cGMP, 2'-deoxyguanosine and many naturally occurring nucleobases, nucleosides, and nucleotides
  [@B5]    tv2       NM153320           HEK293                                Was not expressed at the plasma membrane
  [@B23]   tv3       AF210455           HEK293                                Uric acid
  [@B4]    tv1       NM006672           HEK293                                Penciclovir, acyclovir, ganciclovir
  [@B7]    tv1       NM006672           HEK293                                Orotic acid, glutamate, cGMP, 2'-deoxyguanosine, trigonelline
  [@B19]   ?                            Madin-Darby canine kidney (MDCK) II   cGMP, creatinine
  [@B25]   tv1       NM006672           HEK293                                Penciclovir, cGMP creatinine
  [@B20]   tv1       NM006672           HEK293                                cGMP, irinotecan
  [@B2]    tv1       NM006672           HEK293                                cGMP

The table highlights the OAT2 transcript variant and heterologous expression system used, along with the compounds that were shown to be transported.? indicates that the OAT2 sequence used was not identified in the publication. The GenBank accession numbers shown are for the corresponding nucleotide sequences. The GenBank accession number AI016020 refers to an Expressed Sequence Tag. The GenBank accession numbers for the peptide sequences are as follows -- AY050498 (AAL12496), AF210455 (AAG43523), NM006672 (NP006663), and NM153320 (NP696961).

In preliminary experiments we examined the transport of estrone-3-sulfate and *para*-aminohippurate by OAT2-tv1 expressed in Chinese hamster ovary (CHO) cells, and failed to observe mediated transport, despite previous work indicating that they are OAT2 substrates (**Table [1](#T1){ref-type="table"}**). Since these early studies used different heterologous systems and possibly OAT2 variants, we hypothesized that the discrepancy could be due to the OAT2 variant and/or heterologous expression system used. Thus, the purpose of the present study was to examine the ligand selectivity of OAT2 expressed in a variety of mammalian cells, and to compare this data to previously published data. Interestingly, while we were able to clone OAT2-tv1 from human kidney, and obtained the OAT2-tv2 from a commercial source, we were unsuccessful at amplifying mRNA for OAT2-tv3 from human kidney. Thus, we examined ligand selectivity of OAT2-tv1 and OAT2-tv2 in three different mammalian cell lines -- CHO, HEK, and MDCK cells.

Materials and Methods {#s1}
=====================

Reagents and Chemicals
----------------------

\[^3^H\]*para*-aminohippurate (60 Ci/mmol), \[^3^H\]estrone-3-sulfate (50 Ci/mmol), \[^3^H\]dehydroepiandrosterone sulfate (63 Ci/mmol), \[^14^C\]glutarate (55 mCi/mmol), and \[^14^C\]succinate (54.0 mCi/mmol) were from American Radiochemicals (St. Louis, MO, USA). \[^3^H\]penciclovir (1.1--18.6 Ci/mmol) and \[^3^H\]paclitaxel (6.4 Ci/mmol) were from Moravek Biochemicals (Brea, CA, USA). Ham's F12K medium, Dulbecco's Modified Eagle's Medium (DMEM), fetal bovine serum (Certified, US Origin), 1% penicillin-streptomycin solution, zeocin, hygromycin B, Platinum High Fidelity DNA polymerase and 4--12% Tris-glycine gels were from Life Technologies (Burlington, ON, USA). Custom oligonucleotide primers were synthesized by Integrated DNA Technologies (Coralville, IA, USA). The bicinchoninic acid protein assay kit, Sulfo-NHS-SS-biotin reagent, Streptavidin UltraLink resin and the SuperSignal^®^ West Femto chemiluminescent substrate were from Thermo Scientific (Rockford, IL, USA). All other chemicals were obtained from Sigma--Aldrich (St. Louis, MO, USA). Human kidney cortex from a single donor was obtained from the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD) Brain and Tissue Bank at the University of Maryland (Baltimore, MD, USA). The use of human kidney tissue was approved by the Research Ethics Board of Dalhousie University. Waymouth buffer (WB) used for transport experiments contained (in mM): 135 NaCl, 28 [D]{.smallcaps}-glucose, 5 KCl, 1.2 MgCl~2~, 2.5 CaCl~2~, 0.8 MgSO~4~, and 13 HEPES-NaOH, pH 7.4. Phosphate buffered saline (PBS) containing calcium and magnesium (PBS/CM) used in biotinylation experiments contained (in mM): 137 NaCl, 2.7 KCl, 8 Na~2~HPO~4~, 0.1 CaCl~2~, and 1 MgCl~2~, pH 8.0.

Cloning of the Human Orthologs of OAT2 Transcript Variants 1 and 2
------------------------------------------------------------------

The open reading frame of the human ortholog of OAT2 transcript variant 1 (OAT2-tv1) containing 546 amino acids was amplified from human kidney cDNA. The open reading frame of the human ortholog of OAT2 transcript variant 2 (OAT2-tv2) containing 548 amino acids was amplified from a construct obtained from Origene (model\# SC108270, Rockville, MD, USA) that was contained within the pCMV6-XL4 vector. Platinum High Fidelity DNA Polymerase and sequence-specific oligonucleotide primers were used in the polymerase chain reaction (PCR) reactions. PCR products were purified by gel extraction and the constructs were subcloned into the pcDNA5/FRT/V5-His-TOPO mammalian expression plasmid according to the manufacturer's protocol. The constructs were designed to contain their native stop codon. Plasmid DNA was prepared using the MO BIO Ultra Clean plasmid preparation kit and DNA sequencing (MCLAB, San Francisco, CA, USA) showed that the OAT2-tv1 and OAT2-tv2 constructs corresponded to GenBank Accession number NM006672 and GenBank Accession number NM153320, respectively, as reported in the NCBI database.

Cell Culture and Stable Expression of OAT2-tv1 and OAT2-tv2 Cell Lines
----------------------------------------------------------------------

Chinese hamster ovary Flp-In cells were grown in medium containing Ham's F12 Kaighn's modification medium, 1% penicillin-streptomycin, 10% fetal bovine serum and zeocin (100 μg/ml). HEK Flp-In and MDCK Flp-In cells were grown in DMEM containing 1% penicillin-streptomycin, 10% fetal bovine serum and zeocin (100 μg/ml). CHO, HEK, and MDCK cell lines stably expressing OAT2-tv1 or OAT2-tv2 were generated using electroporation and selection as described previously ([@B10]). The stable OAT2-tv1 and OAT2-tv2 cell lines were grown in the identical medium outlined above, except that the medium contained hygromycin B (200 μg/ml) instead of zeocin. Cells were grown at 37°C in a humidified atmosphere (5% CO~2~/95% air).

RNA Isolation and Reverse Transcription Polymerase Chain Reaction (RT-PCR)
--------------------------------------------------------------------------

Total RNA was purified from cells using the RNeasy Mini Kit according to the manufacturer's instructions. RNA concentration was determined by UV spectrophotometry. RT-PCR was conducted using standard procedures as described previously ([@B18]). The oligonucleotide primer sequences used for amplifying the human ortholog of OAT2-tv1 and OAT2-tv2 were: 5′-CATTGCAACTGAGTCCCAGTG-3′ (sense) and 5′-CAGGAGGAAGTGCAGTGGTA -3′ (antisense).

Cell Surface Biotinylation and Western Blotting
-----------------------------------------------

Cell surface biotinylation was conducted with cells grown in one well of a 12-well plate. Cell surface biotinylation was performed using Sulfo-NHS-SS-biotin (0.5 mg/ml) using procedures identical to that described previously ([@B1]). The biotinylated proteins were separated on 4--12% tris-glycine gels, and transferred to polyvinylidene difluoride membranes. The antibodies used were a polyclonal rabbit anti-human OAT2 antibody (0.5 μg/ml) (Cosmo Bio Ltd., Carlsbad, CA, USA) and a goat anti-rabbit HRP-conjugated secondary antibody (4 μg/ml). The SuperSignal West Femto chemiluminescent (Thermo Scientific) substrate was used for immunoreactivity detection.

Transport Studies Examining Cellular Uptake
-------------------------------------------

All experiments examining cellular radiolabeled compound uptake were conducted using cells grown to confluence in 24-well flat bottom plates. The transport solution consisted of WB (room temperature) containing radiolabeled compound and the uptake period for all experiments was at an initial rate time point of 5 min. \[^3^H\]Penciclovir served as the probe OAT2 substrate. We also examined the uptake of \[^3^H\]*para*-aminohippurate, \[^3^H\]estrone-3-sulfate, \[^14^C\]glutarate, \[^14^C\]succinate, \[^3^H\]paclitaxel, and \[^3^H\]dehydroepiandrosterone sulfate by OAT2 since published studies indicate that they are substrates of the transport protein ([@B26]; [@B15]). To examine the potential for compounds to inhibit OAT2, the transport solution contained \[^3^H\]penciclovir and either a fixed concentration of test compound (1 mM), or increasing concentrations of test compound to determine potency of inhibition (inhibitor concentration 50, IC~50~). For all cellular uptake experiments, the medium was aspirated and the cells were rinsed once with WB (0.3 ml). Following the uptake period, cells were washed three times with ice-cold WB (0.5 ml each wash). After aspirating the final wash the cells were lysed in 0.5 N NaOH/1% SDS (0.4 ml) for ∼30 min on an orbital shaker. 1 N HCl (0.2 ml) was then added to neutralize the NaOH, and the cell lysates (0.5 ml) were transferred to scintillation vials containing liquid scintillation cocktail (CytoScint ES, MP Biomedicals). Cellular radioactivity content was determined with a Beckman LS6500 liquid scintillation counter. Protein content was determined using the bicinchoninic acid method. See the Figure and Table Legends for additional details describing the experimental conditions used.

Data Analysis
-------------

Transport data are reported as the mean ± standard error of the mean of at least three independent experiments using cells of a different passage number. A two-tailed unpaired Student's *t-*test was used for comparisons of means between two groups. Significance for all analyses was assigned at *P* \< 0.05. All graphing, non-linear regression analyses and statistical analyses were performed with GraphPad Prism (version 6.03).

Results
=======

Organic anion transporter 2-tv1 and OAT2-tv2 were individually transfected into CHO, HEK, and MDCK cells, and placed under selection pressure in order to establish stable cell lines. RT-PCR analyses revealed expression of both OAT2-tv1 and OAT2-tv2 at the mRNA level in all three cell types, indicating successful stable expression of both constructs (**Figure [1A](#F1){ref-type="fig"}**). However, cell surface biotinylation experiments showed that only OAT2-tv1 was present at the cell surface (**Figure [1B](#F1){ref-type="fig"}**), pointing to a potential trafficking defect associated with OAT2-tv2.

![**mRNA expression **(A)** and cell surface protein expression **(B)** of Organic anion transporter 2 (OAT2)-tv1 (tv1) or OAT2-tv2 (tv2) in Chinese hamster ovary (CHO), human embryonic kidney (HEK), or Madin-Darby canine kidney (MDCK) cells stably transfected with the respective construct, or in parental cells (P).** mRNA expression was determined by reverse transcription polymerase chain reaction (RT-PCR) using oligonucleotide primers against OAT2. Amplified products were separated on 1% agarose gels and stained with ethidium bromide. Sulfo-NHS-SS-biotin was used for cell surface biotinylation.](fphar-06-00216-g001){#F1}

The uptake of several putative OAT2 substrates was tested in the three different cell types (CHO, HEK, and MDCK) expressing the human orthologs of either OAT2-tv1 or OAT2-tv2 (**Figure [2](#F2){ref-type="fig"}**). Compared to parental cells, the uptake of penciclovir was 21-fold, 39-fold, and 5-fold significantly higher in CHO-OAT2-tv1, HEK-OAT2-tv1, and MDCK-OAT2-tv1 cells, respectively (**Figure [2A](#F2){ref-type="fig"}**). Consistent with its lack of cell surface expression, the uptake of penciclovir into CHO-OAT2-tv2, HEK-OAT2-tv2, and MDCK-OAT2-tv2 cells was not different from uptake into the respective parental cells (**Figure [2A](#F2){ref-type="fig"}**). The uptake of *para*-aminohippurate (**Figure [2B](#F2){ref-type="fig"}**), estrone-3-sulfate (**Figure [2C](#F2){ref-type="fig"}**), or glutarate (**Figure [2D](#F2){ref-type="fig"}**) into CHO, HEK, and MDCK cells expressing either OAT2-tv1 or OAT2-tv2 was not different than uptake into the respective parental cells. Additionally, when expressed in CHO cells, OAT2-tv1 was unable to show mediated transport of two other putative OAT2 substrates, dehydroepiandrosterone sulfate and paclitaxel. The cellular accumulation of \[^3^H\]dehydroepiandrosterone sulfate (12 nM) into CHO parental vs. CHO-OAT2-tv1 cells was 10.3 ± 1.1 fmoles mg protein^-1^ ⋅ min^-1^ vs. 11.0 ± 0.54 fmoles ⋅ mg protein^-1^ ⋅ min^-1^, respectively (*n* = 3). The cellular accumulation of \[^3^H\]paclitaxel (22 nM) into CHO parental vs. CHO-OAT2-tv1 cells was 89 ± 3.8 fmoles ⋅ mg protein^-1^ ⋅ min^-1^ vs. 90 ± 5.1 fmoles ⋅ mg protein^-1^ ⋅ min^-1^ (*n* = 3). Given the similarity in substrate selectivity of OAT2-tv1 regardless of cell type, and the lack of functional expression of OAT2-tv2, all subsequent experiments were done with the CHO-OAT2-tv1 cells.

![**Cellular accumulation of \[^3^H\]penciclovir **(A)**, \[^3^H\]*para*-aminohippurate **(B)**, \[^3^H\]estrone-3-sulfate **(C)**, or \[^14^C\]glutarate **(D)** by parental CHO, HEK, or MDCK cells, or CHO, HEK, or MDCK cells stably expressing either OAT2-tv1 or OAT2-tv2.** The concentration of \[^3^H\]penciclovir in the transport solution was 0.1 μM for CHO and MDCK cell experiments, and 0.5 μM for HEK cell experiments. The concentrations of \[^3^H\]*para*-aminohippurate, \[^3^H\]estrone-3-sulfate and \[^14^C\]glutarate were 8 nM, 10 nM, and 18 μM, respectively. Uptake was conducted for 5 min at room temperature. Values are mean ± standard error of the mean of four experiments. \*Significantly different from parental cells, *P* \< 0.05, two-tailed unpaired student's *t*-test.](fphar-06-00216-g002){#F2}

It was previously reported that succinate and fumarate are capable of trans*-*stimulating OAT2-mediated substrate uptake ([@B15]), suggesting that OAT2 may be an organic anion/dicarboxylate exchanger. Given these previous results we hypothesized that if dicarboxylates interact as substrates of OAT2 that they may also inhibit the transport protein. Thus, we examined the ability of a variety of Kreb's cycle intermediates (succinate, fumarate, α-ketoglutarate, oxaloacetate, citrate, *cis*-aconitate, and [D]{.smallcaps}-malate) to *cis*-inhibit penciclovir uptake into CHO-OAT2-tv1 cells. Even at a high concentration (1 mM), none of the Kreb's cycle intermediates tested, including succinate and fumarate, *cis*-inhibited penciclovir uptake (**Figure [3](#F3){ref-type="fig"}**). Conversely, the OAT2 inhibitors glutamate (1 mM) and furosemide (200 μM) reduced penciclovir uptake by 70--85% compared to control, confirming that OAT2-tv1 was functional (**Figure [3](#F3){ref-type="fig"}**). We also examined the uptake of \[^14^C\]-succinate by CHO-OAT2-tv1 cells to determine if it is in fact a substrate. The uptake of \[^14^C\]succinate by CHO-OAT2-tv1 cells was not different than uptake into the parental CHO cells (**Figure [4](#F4){ref-type="fig"}**). In a single experiment (*n* = 1), the uptake of \[^14^C\]succinate by CHO cells stably expressing the Na-dicarboxylate cotransporter 3 (NaDC3) was ∼30-fold higher than control.

![***Cis*-inhibition of \[^3^H\]penciclovir (∼30 nM) uptake into CHO-OAT2-tv1 cells by Kreb's cycle intermediates.** The concentration of each Kreb's cycle intermediate was 1 mM. Uptake was conducted for 5 min. Glutamate (1 mM) or furosemide (200 μM) were used as positive control inhibitors. Values are the mean ± standard error of the mean from 3 to 4 experiments. \*Significantly different from control (open bar), *P* \< 0.05, two-tailed unpaired Student's *t-*test.](fphar-06-00216-g003){#F3}

![**Cellular accumulation of \[^14^C\]succinate (18.5 μM) by CHO parental cells, CHO-OAT2-tv1 cells or CHO cells stably expressing the Na-dicarboxylate cotransporter 3 (NaDC3).** Uptake was conducted for 5 min. Values are the mean ± standard error of the mean of four experiments for CHO parental and CHO-OAT2-tv1 cells. A single uptake experiment was performed with CHO-NaDC3 cells. There was no significant difference in \[^14^C\]succinate uptake by CHO-OAT2-tv1 cells compared to parental CHO cells (*P* \> 0.05, two-tailed unpaired student's *t*-test.](fphar-06-00216-g004){#F4}

Given the results that previously identified substrates (*para*-aminohippurate, estrone-3-sulfate, glutarate, dehydroepiandro sterone sulfate, paclitaxel, and succinate) were not transported by OAT2-tv1 in the present study led us to examine the inhibitory potential of a variety of drugs (organic anions, cations, and neutral molecules) against OAT2-tv1. A total of seventeen compounds with diverse physicochemical properties were tested for their potency to inhibit penciclovir uptake by CHO-OAT2-tv1 cells (**Table [2](#T2){ref-type="table"}**). The majority of organic anions tested were effective inhibitors, reducing penciclovir uptake by ≥85% of the control level. These compounds inhibited with varying degrees of potency ranging from 3.7 μM (indomethacin) to 210 μM (*para*-aminohippurate). Methotrexate (76%), probenecid (64%), and cidofovir (53%) were also capable of reducing OAT2-tv1-mediated penciclovir uptake, but the effect was not dose-dependent, so IC~50~ values could not be determined. The organic cations and neutral compounds also showed varying abilities to inhibit OAT2-tv1. Notably, cimetidine and allopurinol each inhibited 95% of transport activity, with IC~50~ values of 57 and 70 μM, respectively.

###### 

Potency of OAT2-tv1 inhibition by organic molecules with diverse physicochemical properties.

  Test compound           Maximum concentration (μM)   \% Inhibition   IC~50~ (μM)   MW
  ----------------------- ---------------------------- --------------- ------------- --------
  **Organic anions**                                                                 
  Indomethacin            1000                         99              3.7 ± 0.5     357.8
  Repaglinide             500                          99              30.0 ± 3.6    452.6
  *para-*aminohippurate   1000                         99              210.3 ± 77    194.2
  Telmisartan             200                          96              17.1 ± 1.3    514.6
  Prostaglandin E2        500                          96              26.8 ± 2.4    352.5
  Estrone Sulfate         1000                         95              36.1 ± 3.9    372.4
  Furosemide              200                          90              10.8 ± 1.5    330.7
  Valsartan               1000                         86              126.9 ± 29    435.5
  Methotrexate            1000                         76              ND            454.4
  Probenecid              1000                         64              ND            285.4
  Cidofovir               1000                         53              ND            279.2
  **Organic cations**                                                                
  Cimetidine              1000                         95              57.2 ± 14     252.3
  Erythromycin            1000                         65              12.0 ± 5.4    733.9
  Cyclosporin A           62.5                         55              8.6 ± 4.9     1202.6
  Tetrapentylammonium     1000                         49              278.8 ± 142   378.5
  Tetraethylammonium      1000                         42              54.3 ± 33     210.2
  **Neutral compounds**                                                              
  Allopurinol             1000                         95              70.1 ± 34     136.1
  Penciclovir             1500                         85              78.4 ± 8.2    253.3

\[

3

H\] Penciclovir (∼30 nM) was the substrate. Uptake was conducted for 5 min at room temperature in the presence of increasing concentrations of test compound. The maximum concentration of test compound used is indicated. The potency of inhibition (IC

50

determination) was determined by non-linear regression analysis. IC

50

values are the mean ± standard error of the mean of 3--4 experiments. The % inhibition corresponds to the percent reduction in transport, compared to parental cells, that was achieved by the maximum drug concentration tested. ND, the IC

50

could not be determined by non-linear regression analysis. MW, test compound molecular weight (grams/mol).

Discussion
==========

In the present study we cloned and stably expressed OAT2-tv1 and OAT2-tv2 in three different mammalian cell lines in order to examine their ligand selectivity. Unexpectedly, several attempts to amplify OAT2-tv3 mRNA from human kidney were unsuccessful. OAT2-tv3 was cloned by [@B6], and in their manuscript they reference GenBank accession\# AF210455 as the corresponding nucleotide sequence. According to NCBI, this OAT2 construct was originally cloned from human kidney with the authorship listed as: Reid G, Bahn A, Ebbinghaus C, Wolff NA, and Burckhardt G (deposited in 2001). Also of interest, there are several studies that have examined the ligand selectivity of OAT2, where the sequence used was not cited \[([@B26]; [@B3]; [@B12], [@B11]; [@B14]; [@B27]; [@B16]; [@B19]); **Table [1](#T1){ref-type="table"}**\]. Like the [@B6] study that described the cloning of OAT2-tv3, most of these other studies had the same senior author, suggesting that OAT2-tv3 may have been used in these other studies as well. However, since the exact sequence used was not cited in these manuscripts, we cannot be certain that this is the case.

OAT2-tv3 shares 97% sequence identity with OAT2-tv1 and OAT2-tv2. The OAT2-tv3 amino acid sequence differs from OAT2-tv1 and OAT2-tv2 primarily in its C-terminal end (Supplemental Figure [S1](#SM1){ref-type="supplementary-material"}). Amino acid alignment of OAT2 from human (OAT2-tv1 and OAT2-tv3), mouse, rat, rabbit, cattle, pig, horse, opossum, and chicken indicates that the C-terminal end varies across species as well (Supplemental Figure [S2](#SM2){ref-type="supplementary-material"}). Interestingly, there are a greater number of conserved amino acids at homologous positions in the C-terminal of OAT2 from other species (except mouse) and OAT2-tv1, than with OAT2-tv3 (Supplemental Figure [S2](#SM2){ref-type="supplementary-material"}). A BLAST search of the human genome in NCBI using the OAT2-tv3 cDNA sequence as the query results in OAT2-tv1 and OAT2-tv2 as hits, but not OAT2-tv3. The OAT2-tv3 sequence was also not found in the NHLBI Exome Sequencing Project Exome Variant Server database (<http://evs.gs.washington.edu/EVS/>). Future studies should be directed at determining if OAT2-tv3 actually exists, and if so, its tissue, cellular and subcellular distribution, as well as how its sequence variation affects ligand selectivity.

When expressed in either CHO, MDCK, or HEK cells, OAT2-tv2 was non-functional. While OAT2-tv2 expression at the mRNA level in each of the cell lines was detected, cell surface biotinylation experiments indicated that the protein was not present at the plasma membrane, unlike OAT2-tv1, which showed clear plasma membrane expression. OAT2-tv2 has an additional serine and glutamine at amino acid positions 132 and 133, respectively. Homology modeling was previously used to predict the tertiary structure of OAT1 ([@B22]), which is related to OAT2. Supplemental Figure [S3](#SM3){ref-type="supplementary-material"} shows an amino acid alignment between the first ∼200 amino acids of OAT1, OAT2-tv1, and OAT2-tv2. The figure highlights the position of transmembrane helices 1 and 2, as well as the long extracellular loop in the OAT1 model. Assuming similar topologies between OAT1 and OAT2, the additional two amino acids in OAT2-tv2 are expected to occur in the long extracellular loop between transmembrane helices 1 and 2 (Supplemental Figure [S3](#SM3){ref-type="supplementary-material"}) -- these two amino acids were also predicted to be in the putative long extracellular loop of OAT2 using HMMTOP 2.0. Several studies have shown that modification of amino acids in the long extracellular loop of OAT1 (as well as other related SLC drug transporters) has a profound influence on its plasma membrane expression ([@B28],[@B29]), and given these results, the insertion of two additional amino acids in the long loop of OAT2 may affect its protein folding and trafficking. Consistent with this hypothesis, [@B5] showed by immunocytochemistry that OAT2-tv2 protein in HEK cells is retained in an intracellular compartment. Alternatively, the OAT2-tv2 variant may have an increased rate of protein degradation ([@B5]). While OAT2-tv2 shows no apparent expression at the plasma membrane of any mammalian cell tested to date, it was clearly expressed and functional in *X. laevis* oocytes ([@B15]) (**Table [1](#T1){ref-type="table"}**). This raises the question of the most appropriate heterologous system for studying mammalian transport proteins, and what the functional role, if any, OAT2-tv2 has in human tissues. [@B5] showed that mRNA for OAT2-tv2 is expressed at similar levels to OAT2-tv1 in a variety of tissues. Perhaps OAT2-tv2 has a role in transporting its substrates across intracellular membranous compartments.

Several early studies that have helped define the substrate selectivity of human OAT2 were done using a construct with an undefined sequence or OAT2-tv2 expressed in *Xenopus* oocytes (**Table [1](#T1){ref-type="table"}**), which is non-functional in all mammalian cells tested to date. In particular, early studies have suggested that *para*-aminohippurate, estrone-3-sulfate, glutarate, dehydroepiandrosterone sulfate, paclitaxel, among others, are human OAT2 substrates (**Table [1](#T1){ref-type="table"}**). Importantly, according to nearly all reviews on organic anion transport, the aforementioned compounds are listed as substrates of human OAT2 \[e.g., ([@B30])\]. Yet, we showed that OAT2-tv1 does not transport these organic anions in the cell types tested, but did transport penciclovir in all three cell types. Together, these data indicate that the substrate selectivity of OAT2-tv1 is similar in CHO, HEK, and MDCK cells. [@B5] also failed to observe appreciable uptake of *para*-aminohippurate by HEK-OAT2-tv1 cells. Also consistent with our results, [@B26] did not observe transport of dehydroepiandrosterone sulfate by OAT2 -- although it is unclear what variant was used in their study. Despite not observing transport of *para*-aminohippurate, estrone-3-sulfate, glutarate, dehydroepiandrosterone sulfate, or paclitaxel, we did show robust transport of penciclovir by OAT2-tv1, which has been demonstrated previously ([@B4]; [@B25]). When expressed in S2 cells, OAT2 (sequence not given) failed to transport acyclovir or ganciclovir ([@B27]), yet, these antivirals, along with penciclovir, are clearly substrates of OAT2-tv1 ([@B4]). Interestingly, most recent studies examining ligand selectivity of OAT2 have used transcript variant 1, as opposed to the other variants (**Table [1](#T1){ref-type="table"}**).

Information regarding the transport mechanism of OAT2 is limited to only a few studies that used either human, mouse or rat orthologs of OAT2. Transport by all three orthologs is Na-independent ([@B24]; [@B17], [@B15]). [@B7] showed that OAT2-tv1 in HEK cells can mediate orotic acid/orotic acid and orotic acid/glutamate exchange. Uptake of estrone-3-sulfate by OAT2-tv2 in *Xenopus* oocytes was modestly stimulated by pre-loading the oocytes with 5 mM fumarate (1.7-fold stimulation) or succinate (2.1-fold), suggesting an anion exchange mechanism involving either of these Kreb's cycle intermediates ([@B15]). In contrast, [@B23] failed to observe stimulation of urate uptake by OAT2-tv3 in HEK cells pre-loaded with succinate (100 mM). Given these discrepancies with succinate, we tested the *cis*-inhibitory effect of a variety of Kreb's cycle intermediates (including fumarate and succinate) with OAT2-tv1. However, none of the Kreb's cycle intermediates tested (at 1 mM) inhibited transport of penciclovir by OAT2-tv1. Similar to our results, [@B2] did not observe *cis*-inhibition of OAT2-tv1-mediated cGMP transport by citrate or *cis*-aconitate. We further showed that, indeed, \[^14^C\]succinate is not transported by OAT2-tv1 in CHO cells. Our data, along with those of [@B23], suggest that at least succinate is not translocated by OAT2-tv1. This raises the question -- what is the driving force for OAT2-mediated substrate uptake into cells? Glutamate is an abundant intracellular amino acid (2--20 mM; [@B21]), and [@B7] showed that the outwardly directed glutamate gradient can stimulate OAT2-tv1-mediated substrate uptake via an exchange mechanism. Thus, as previously suggested ([@B7]), glutamate is a good candidate for a physiological trans-substrate for OAT2-tv1-mediated translocation.

Given that several previously identified substrates were not transported by OAT2-tv1 in the present study, we also examined the inhibitory potential of a variety of organic compounds against OAT2-tv1. To our knowledge, many of the compounds tested have not been previously examined for their inhibition potency against OAT2, including repaglinide, *para*-aminohippurate, telmisartan, estrone-3-sulfate, valsartan, methotrexate, cidofovir, tetrapentylammonium, tetraethylammonium, and allopurinol. The IC~50~ values that we obtained for inhibition of OAT2-tv1 by indomethacin (3.7 μM), furosemide (10.8 μM), cyclosporine A (8.6 μM), and cimetidine (57.2 μM) are in good agreement with other studies examining the potency with which these compounds inhibit OAT2-tv1 -- indomethacin \[2.1 μM; ([@B25])\], furosemide \[10.9 μM; ([@B2])\], cyclosporine A \[11.1 μM; ([@B25])\], and cimetidine \[62.3; ([@B25])\]. In contrast, there is an inconsistency between our data and studies examining the inhibitory potency of several of these compounds against OAT2 with an unidentified sequence -- indomethacin \[64.1 μM; ([@B12])\], furosemide \[603 μM; ([@B9])\] and cimetidine \[no inhibition; ([@B13])\]. Also at odds is the observation that allopurinol is a substrate ([@B5]) and inhibitor (present study) of OAT2-tv1, but did not inhibit uric acid transport by OAT2-tv3 in HEK293 cells ([@B23]). Our data also showed that transport of penciclovir by OAT2-tv1 is sensitive to large (e.g., cyclosporine A) and small (e.g., allopurinol) organic compounds, and organic anions, cations as well as neutral compounds, highlighting the multiselectivity of the OAT2-tv1 ligand binding surface.

In summary, data from the literature on ligand selectivity of OAT2 is complicated by the fact that there are apparently three transcript variants, and many of the studies failed to identify the transcript variant that was used. Previously identified substrates of OAT2-tv2 expressed in *Xenopus* oocytes, including *para*-aminohippurate, succinate, glutarate, estrone-3-sulfate, paclitaxel, or dehydroepiandrosterone sulfate, are not transported by OAT2-tv1. For the limited number of compounds tested, the substrate selectivity of OAT2-tv1 was qualitatively similar regardless of the cell type in which it was expressed. Interestingly, OAT2-tv2 did not express at the plasma membrane of any of the three mammalian cell types examined. There was also a discrepancy between potency of several compounds to inhibit OAT2-tv1 in the present study, and previously published data using OAT2 with an unidentified sequence. OAT2-tv1 was inhibited by compounds with diverse physicochemical properties, making it a potential site of drug--drug interactions. Future studies using OAT2 for ligand interaction studies should identify the transcript variant being used. Additional studies are required to determine the expression pattern and functional activity of OAT2-tv3.
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